TotalMarketCap

4D Molecular Therapeutics

FDMTNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$621.774 M

$11.26 -8.35%

Close of 6 Nov 2026

As of 6 Nov 2026, 4D Molecular Therapeutics (FDMT) has a market capitalization of $621.8M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$85.2M

#2541 by revenue

Earnings

-$140.1M

Loss-making

Shares outstanding

55,214,097

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #56Ginkgo BioworksDNA$646.9M
  2. #57Bambusa TherapeuticsBBTX$631.2M
  3. #584D Molecular TherapeuticsFDMT$621.8M
  4. #59Candel TherapeuticsCADL$615.6M
  5. #60DBV TechnologiesDBVT$614.9M

What if 4D Molecular Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$511,128.19

Per share 45,413× higher

Bitcoin $1.53T

$27,656.26

Per share 2,457× higher

Apple $5.02T

$90,792.91

Per share 8,067× higher

Or at a round number

$1.00B$2.00B$5.00B$10.0B

Where these numbers come from

Share counts and financials for 4D Molecular Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.